Idenix Pharmaceuticals, Inc. · Cambridge, MA United States ·(NASDAQ (GM): IDIX)

Idenix Pharmaceuticals is not suffering from any identity crisis -- it is clear in its focus on identifying treatments for life-threatening viruses. The biopharmaceutical firm is developing orally administered drugs to combat chronic hepatitis C (HCV) and HIV. Its lead HIV product candidate is in early clinical stages; its HCV candidates are in preclinical testing. Most are intended to be taken in combination with other therapeutic agents to improve efficacy and convenience. Under a development and commercialization agreement, Novartis has the option to license any of the product candidates developed by Idenix. Novartis owns 56% of Idenix. To read the full description, subscribe now.